Gender Disparities in Statin Prescriptions in People With HIV With Low/Moderate to High Cardiovascular Risk.

ABSTRACT: The REPRIEVE trial suggests that primary cardiovascular disease (CVD) prevention could be considered among people with HIV at low CVD risk. We found cisgender women with low/moderate and high CVD risk are less likely to receive statins than cisgender men. Efforts are needed to guarantee equal access to statin-based CVD prevention.

SUBMITTER: Abela IA 

PROVIDER: S-EPMC11409876 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature